5 May 2016 - The Transparency Commission will consider the reimbursement of golimumab (Simponi), metyrapone (Metyrapone HRA Pharma) and tiotropium bromide monohydrate with olodaterol hydrochloride (Spiolto Respimat).

The Commission will also review the SMR &/or ASMR ratings for a number of cancer medicines.

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-05/ordre_du_jour_ct_11052016_internet.pdf